Mirus Bio Develops New Antibody Production Technique
Posted on: Thursday, 16 March 2006, 21:00 CST
Scientists at Mirus Bio Corporation have developed a genetic immunization technique that they say allows for the production of high-quality antibodies faster and more cheaply than by conventional methods.
The new process, described in the journal BioTechniques, involves an new method of intravenously injecting DNA into animals, whose immune systems respond by producing antibodies that can be harvested for subsequent use.
Antibodies are part of the body's immune system. Because they can bind to and neutralize specific antigens, such as proteins, viruses, and cancer cells, they have become useful tools in medical diagnosis and scientific research. Antibodies are also used for the targeted treatment of diseases, such as cancer.
Conventional methods of generating antibodies require the slow process of identifying, isolating, and purifying the protein which serves as the target antigen, before it can be injected into the animal in order to elicit the desired antibody response.
However, due to the processes employed, such purified proteins may not be identical to the natural antigenic protein, and therefore may not be as potent at eliciting an immune response. They can also be very difficult to manufacture
"The new technique developed at Mirus Bio bypasses these hurdles and enables research animals to naturally produce antigenic proteins that elicit a potent antibody response. This offers a higher quality antibody in less time at reduced cost," said the company in a statement.
Source: Datamonitor
Related Articles
- HIV-1 Damages Gut Antibody-producing immune Cells Within Days Of Infection
- Nabi Biopharmaceuticals Announces Successful Final Results of NicVAX(R) Immunogenicity Study; Increased Antibody Response Sustained in Vast Majority of Subjects
- Intellect Neurosciences, Inc. Obtains Pivotal European Patent Related To Monoclonal Antibody Passive Immunization Treatment Of Alzheimer's Disease
- Nabi Biopharmaceuticals Announces Positive Interim Results of NicVAX Immunogenicity Study; Revised Schedule Significantly Increases Antibody Response in Vast Majority of Subjects
- Vical's Vaxfectin(TM) Adjuvant With Needle-Free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
- Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
- Cambridge Antibody Technology Licenses Monoclonal Antibody (CAT-213) for Treatment of Allergy Disorders to iCo Therapeutics
- Higher Antibody Responses Observed in Young Children Receiving MedImmune's Investigational Intranasal Influenza Vaccine Compared to Injectable Vaccine
- Phase 3 Trial of Insegia in Pancreatic Cancer Does Not Meet Primary Endpoint; Survival Advantage Seen in Patients Who Achieve Antibody Response
- Heat Shock Protein Antibody Titers Are Reduced By Statin Therapy in Dyslipidemic Subjects: A Pilot Study
 |
 |
User Comments (0)
RSS Feeds